A mother’s routine ER visit for dehydration uncovered stage 4 colorectal cancer with no symptoms, leading to a pioneering liver transplant that erased her disease in just three months.
Story Highlights
- Amy Piccioli, 39-year-old Los Angeles mother of three, diagnosed asymptomatically via CT scan.
- Underwent chemotherapy, tumor removal, then Northwestern Medicine’s first living donor liver transplant for metastatic colon cancer in December 2025.
- Three months post-transplant in April 2026, reports no evidence of disease and feels completely normal.
- Five-year survival jumps from 10% with chemo alone to 60-80% via transplant in selected patients.
- Highlights rarity of transplant oncology programs and living donor success.
Asymptomatic Diagnosis Shocks Healthy Mother
Amy Piccioli visited the ER in 2024 thinking she had dehydration from a stomach bug. A CT scan revealed a colon mass and multiple liver lesions, confirming stage 4 colorectal cancer. Despite zero symptoms, doctors started chemotherapy and immunotherapy in June 2024. Scans in September showed tumors shrinking significantly. She later had surgery to remove the colon tumor. This unexpected discovery propelled her toward innovative treatment at Northwestern Medicine in Chicago.
Living Donor Transplant Breaks New Ground
Friend Lauren Prior matched as living donor in fall 2025. Surgeons performed the partial liver transplant in December 2025, marking Northwestern’s first for metastatic colon cancer. The procedure replaced Piccioli’s diseased liver segment with healthy tissue from Prior. Both recovered well. Piccioli stayed in Chicago through March 2026 for monitoring. By April, blood tests showed no residual cancer cells. She resumed workouts and work as a CPA.
Northwestern’s Specialized Program Drives Success
Northwestern Medicine runs one of few U.S. programs for colorectal cancer liver transplants. Dr. Satish Nadig, transplant center director, stresses chemotherapy response as the gatekeeper for eligibility. Patients need cancer confined to the liver without nearby invasion. Dr. Zachary C. Dietch performed the surgery, noting precise timing of chemo, imaging, and therapy. Dr. Andres Duarte oversees selection, ensuring complete cancer eradication potential. Multidisciplinary coordination sets this apart.
Expert consensus aligns on rigorous selection yielding superior outcomes. Survival data supports transplants over chemo alone, aligning with values of maximizing life through proven innovation and personal responsibility in health screening.
Survival Odds Transform from Dismal to Hopeful
Chemo alone offers 10% five-year survival for unresectable colorectal liver metastases. Transplants boost this to 60-80% in selected cases, with some achieving cures. Piccioli’s outcome validates this shift in transplant oncology. Her story boosts awareness for patients facing terminal prognoses. She now urges: ask about transplants if cancer spreads to the liver. Media coverage amplifies calls for broader access to such programs.
Short-term wins include Piccioli’s return to family life; long-term, potential policy shifts on insurance and guidelines. Economic trade-offs favor transplants over endless palliative care, emphasizing efficient resource use.
Patient Advocacy and Future Implications
Piccioli advocates for transplant options unknown to many oncologists outside specialized centers. Her friendship-driven donation highlights living donor viability. Northwestern’s reputation grows, possibly spurring referrals and expansions. Families gain extended time; communities see precision medicine triumphs. Uncertainties remain on long-term data, but early success demands attention to screening and bold treatments.
Sources:
Mom with no symptoms had stage 4 colorectal cancer. Rare surgery saved her life
Stage 4 Colorectal Cancer: A Liver Transplant Surgery Breakthrough
Woman with stage 4 cancer has ‘no evidence of disease’ after life-changing transplant
